Samal Bissenova

Ms. Samal Bissenova

KU Leuven, Leuven, Belgium
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2020 in Diabetes
Verified
Journal Article
Open access
PDF file
FSFernanda M.C. Sodré
Fernanda M.C. Sodré
SBSamal Bissenova
Samal Bissenova
YBYlke Bruggeman
Ylke Bruggeman
RTRonak Tilvawala
Ronak Tilvawala
DCDana P. Cook
Dana P. Cook
LOLut Overbergh
Lut Overbergh
Protein citrullination plays a role in several autoimmune diseases. Its involvement in murine and human type 1 diabetes has recently been recognized through the discovery of antibodies and T-cell reactivity against citrullinated peptides. In the current study, we demonstrate that systemic inhibition of peptidylarginine deiminases (PADs), the enzymes mediating citrullination, through BB-Cl-amidine treatment, prevents diabetes development in NOD mice. This prevention was associated with reduced levels of citrullination in the pancreas, decreased circulating autoantibody titers against citrullinated glucose-regulated protein 78, and reduced spontaneous neutrophil extracellular trap formation of bone marrow–derived neutrophils. Moreover, BB-Cl-amidine treatment induced a shift from Th1 to Th2 cytokines in the serum and an increase in the frequency of regulatory T cells in the blood and spleen. In the pancreas, BB-Cl-amidine treatment preserved insulin production and was associated with a less destructive immune infiltrate characterized by reduced frequencies of effector memory CD4+ T cells and a modest reduction in the frequency of interferon-γ–producing CD4+ and CD8+ T cells. Our results point to a role of citrullination in the pathogenesis of autoimmune diabetes, with PAD inhibition leading to disease prevention through modulation of immune pathways. These findings provide insight in the potential of PAD inhibition for treating autoimmune diseases like type 1 diabetes.

8 October 2022 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
SBSamal Bissenova
Samal Bissenova
DEDarcy Ellis
Darcy Ellis
CMChantal Mathieu
Chantal Mathieu
CGConny Gysemans
Conny Gysemans
Summary: Neutrophils were long considered to be a short-lived homogenous cell population, limited to their role as first responders in anti-bacterial and -fungal immunity. While it is true that neutrophils are first to infiltrate the site of infection to eliminate pathogens, growing evidence suggests their functions could extend beyond those of basic innate immune cells. Along with their well-established role in pathogen elimination, utilizing effector functions such as phagocytosis, degranulation, and the deployment of neutrophil extracellular traps (NETs), neutrophils have recently been shown to possess antigen-presenting capabilities. Moreover, the identification of different subtypes of neutrophils points to a multifactorial heterogeneous cell population with great plasticity in which some subsets have enhanced pro-inflammatory characteristics, while others seem to behave as immunosuppressors. Interestingly, the aberrant presence of activated neutrophils with a pro-inflammatory profile in several systemic and organ-specific autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS), and type 1 diabetes (T1D) could potentially be exploited in novel therapeutic strategies. The full extent of the involvement of neutrophils, and more specifically that of their various subtypes, in the pathophysiology of autoimmune diseases is yet to be elucidated.

20 July 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
RERuth A Ettinger
Ruth A Ettinger
MBMijke Buitinga
Mijke Buitinga
CVCéline Vandamme
Céline Vandamme
GAGeorgia Afonso
Georgia Afonso
RGRebecca Gomez
Rebecca Gomez
Eddie A. JamesEddie A. James
Eddie A. James
Context: Validated assays to measure autoantigen-specific T-cell frequency and phenotypes are needed for assessing the risk of developing diabetes, monitoring disease progression, evaluating responses to treatment, and personalizing antigen-based therapies. Objective: Toward this end, we performed a technical validation of a tetramer assay for HLA-DRA-DRB1*04:01, a class II allele that is strongly associated with susceptibility to type 1 diabetes (T1D). Methods: HLA-DRA-DRB1*04:01-restricted T cells specific for immunodominant epitopes from islet cell antigens GAD65, IGRP, preproinsulin, and ZnT8, and a reference influenza epitope, were enumerated and phenotyped in a single staining tube with a tetramer assay. Single and multicenter testing was performed, using a clone-spiked specimen and replicate samples from T1D patients, with a target coefficient of variation (CV) less than 30%. The same assay was applied to an exploratory cross-sectional sample set with 24 T1D patients to evaluate the utility of the assay. Results: Influenza-specific T-cell measurements had mean CVs of 6% for the clone-spiked specimen and 11% for T1D samples in single-center testing, and 20% and 31%, respectively, for multicenter testing. Islet-specific T-cell measurements in these same samples had mean CVs of 14% and 23% for single-center and 23% and 41% for multicenter testing. The cross-sectional study identified relationships between T-cell frequencies and phenotype and disease duration, sex, and autoantibodies. A large fraction of the islet-specific T cells exhibited a naive phenotype. Conclusion: Our results demonstrate that the assay is reproducible and useful to characterize islet-specific T cells and identify correlations between T-cell measures and clinical traits.

5 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
SBSamal Bissenova
Samal Bissenova
DEDarcy Ellis
Darcy Ellis
ACAïsha Callebaut
Aïsha Callebaut
GEGuy Eelen
Guy Eelen
RDRita Derua
Rita Derua
LOLut Overbergh
Lut Overbergh
Background and aims: Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by a T-cell-mediated destruction of the pancreatic insulin-producing beta cells. A growing body of evidence suggests that abnormalities in neutrophils and neutrophil extracellular trap (NET) formation (NETosis) are associated with T1D pathophysiology. However, little information is available on whether these changes are primary neutrophil defects or related to the environmental signals encountered during active disease. Methods: In the present work, the NET proteome (NETome) of phorbol 12-myristate 13-acetate (PMA)- and ionomycin-stimulated neutrophils from people with established T1D compared to healthy controls (HC) was studied by proteomic analysis. Results: Levels of NETosis, in addition to plasma levels of pro-inflammatory cytokines and NET markers, were comparable between T1D and HC subjects. However, the T1D NETome was distinct from that of HC in response to both stimuli. Quantitative analysis revealed that the T1D NETome was enriched in proteins belonging to metabolic pathways (i.e., phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, and UTP-glucose-1-phosphate uridylyltransferase). Complementary metabolic profiling revealed that the rate of extracellular acidification, an approximate measure for glycolysis, and mitochondrial respiration were similar between T1D and HC neutrophils in response to both stimuli. Conclusion: The NETome of people with established T1D was enriched in metabolic proteins without an apparent alteration in the bio-energetic profile or dysregulated NETosis. This may reflect an adaptation mechanism employed by activated T1D neutrophils to avoid impaired glycolysis and consequently excessive or suboptimal NETosis, pivotal in innate immune defence and the resolution of inflammation.

19 June 2023 in Biology
Verified
Journal Article
Open access
PDF file
SBSamal Bissenova
Samal Bissenova
MBMijke Buitinga
Mijke Buitinga
MBMarkus Boesch
Markus Boesch
HKHannelie Korf
Hannelie Korf
KCKristina Casteels
Kristina Casteels
CGConny Gysemans
Conny Gysemans
Neutrophils might play an important role in the pathogenesis of autoimmune diseases, including type 1 diabetes (T1D), by contributing to immune dysregulation via a highly inflammatory program called neutrophil extracellular trap (NET) formation or NETosis, involving the extrusion of chromatin entangled with anti-microbial proteins. However, numerous studies reported contradictory data on NET formation in T1D. This might in part be due to the inherent heterogeneity of the disease and the influence of the disease developmental stage on neutrophil behavior. Moreover, there is a lack of a standardized method to measure NETosis in an unbiased and robust manner. In this study, we employed the Incucyte® ZOOM live-cell imaging platform to study NETosis levels in various subtypes of adult and pediatric T1D donors compared to healthy controls (HC) at baseline and in response to phorbol–myristate acetate (PMA) and ionomycin. Firstly, we determined that the technique allows for an operator-independent and automated quantification of NET formation across multiple time points, which showed that PMA and ionomycin induced NETosis with distinct kinetic characteristics, confirmed by high-resolution microscopy. NETosis levels also showed a clear dose-response curve to increasing concentrations of both stimuli. Overall, using Incucyte® ZOOM, no aberrant NET formation was observed over time in the different subtypes of T1D populations, irrespective of age, compared to HC. These data were corroborated by the levels of peripheral NET markers in all study participants. The current study showed that live-cell imaging allows for a robust and unbiased analysis and quantification of NET formation in real-time. Peripheral neutrophil measures should be complemented with dynamic quantification of NETing neutrophils to make robust conclusions on NET formation in health and disease.

30 September 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GSGabriele Sassi
Gabriele Sassi
PLPierre Lemaitre
Pierre Lemaitre
LCLaia Fernández Calvo
Laia Fernández Calvo
FLFrancesca Lodi
Francesca Lodi
ÁCÁlvaro Cortés Calabuig
Álvaro Cortés Calabuig
CGConny Gysemans
Conny Gysemans
Teplizumab, a humanized anti-CD3 mAb, represents a breakthrough in autoimmune type 1 diabetes (T1D) treatment, by delaying clinical onset in stage 2 and slowing progression in early stage 3 of the disease. However, therapeutic responses are heterogeneous. To better understand this variability, we applied single-cell transcriptomics to paired peripheral blood and pancreas samples from anti–mouse CD3–treated nonobese diabetic (NOD) mice and identified distinct gene signatures associated with the therapy outcome, with consistent patterns across compartments. Success-associated signatures were enriched in NK or CD8 + T cells and other immune cell types, whereas resistance signatures were predominantly expressed by neutrophils. The immune cell communities underlying these response signatures were confirmed in human whole blood sequencing data from the Autoimmunity-blocking Antibody for Tolerance (AbATE) study at 6 months, which assessed teplizumab therapy in individuals with stage 3 T1D. Furthermore, baseline expression profiling in the human TrialNet Anti-CD3 Prevention (TN10) (stage 2) and AbATE (stage 3) cohorts identified immune signatures predictive of therapy response, T cell–enriched signatures in responders, and neutrophil-enriched signatures in nonresponders, highlighting the roles of both adaptive and innate immunity in determining teplizumab treatment outcomes. Using an elastic net logistic regression model, we developed a 26-gene blood-based signature predicting the response to teplizumab (AUC = 0.97). These findings demonstrate the predictive potential of immune gene signatures and the value of transcriptomics profiling in guiding individualized treatment strategies with teplizumab in individuals with T1D.